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Objective. Investigate whether CXCR3 and its ligands were involved in the pathogenesis of primary biliary cirrhosis (PBC) in an
autoimmune cholangitis animal model. Methods. Female C57BL/6 mice were injected with 5mg/kg of poly I:C intraperitoneally
twice a week for 24 weeks. PBC model was conﬁrmed by liver function, serum autoantibodies and liver biopsy. Lymphocytes
subsets in liver and spleen and CXCL10 serum level were tested by ﬂow cytometry and ELISA. Liver specimens were collected
to evaluate the diﬀerences in pathology between WT and CXCR3−/− mice. Results. Antimitochondrial antibody was detected
in all PBC model. Numbers of inﬁltrates were detected in the portal areas 8 weeks after poly I:C injection, which progressed
up to 24 weeks. Compared to control mice, CXCL10 serum level increased in PBC mice and the proportion of CXCR3+ cells
increased in the intrahepatic inﬁltrates of PBC mice, chieﬂy on CD8+ cells, whereas the expression of CXCR3 on CD3+ and CD8+
splenocytes decreased in PBC model. Compared with WT mice, CXCR3−/− mice developed delayed and milder progression of
cellular inﬂammation. Conculsions. CXCR3 might contribute to the development of PBC in murine model. Knockout of CXCR3
might delay and alleviate the PBC disease progression, but could not entirely block the disease development.
1.Introduction
Primary biliary cirrhosis (PBC) is an organ-speciﬁc autoim-
mune disease characterized by chronic, progressive destruc-
tion of small intrahepatic bile duct with portal inﬂammation
and ultimately ﬁbrosis. Current theories on the pathogenesis
of PBC have favored the hypothesis that T lymphocytes
played a pivotal role in the autoimmune response in PBC [1,
2]. The liver-inﬁltrating T cells in PBC might be responsible
for damaging the liver and causing chronic liver disease.
Chemokines played a signiﬁcant role in regulating the
development, diﬀerentiation, and location of leukocytes,
controlling the migration of immune cells. The chemokine
receptors are divided into four subfamilies: CXC, CC, C,
CX3C, according to the residual number and arrangement
of N-terminal cysteines in their corresponding chemokine
ligands. It was reported that CX3CL1 played great role
in biliary inﬂammation in primary biliary cirrhosis [3].
CXCR3,oneofthechemokinereceptors,wasfoundpredom-
inantly on T cells has three diﬀerent ligands: IFN-inducible
protein 10 (IP-10)/CXCL10, monokine induced by IFN-γ
(Mig)/CXCL9, and IFN-inducible T cell α chemoattractant
(ITAC)/CXCL11 [4–6], playing a critical role in the recruit-
ment of T cells to inﬂammatory sites and regulating T cell
activation [7].
The expression of CXCR3 has been reported to play
a crucial role in development of several immunological
disease states (e.g., systemic lupus erythematosus, multiple
sclerosis, rheumatoid arthritis, psoriasis, dermatomyositis,
and inﬂammatory bowel disease) [8–18]. In addition, it
was reported that CXCR3 and its ligands contributed to
the development of necroinﬂammatory liver damage and
progression towards ﬁbrosis in chronic HCV patients [19–
28] and other virus-infected liver diseases [29, 30], which
implied the possible involvement of chemokine (IP-10 and
MIG)-chemokine receptor (CXCR3) interactions in the
pathogenesis of PBC [31, 32]. Although studies in human
PBC have shown the presence of CXCR3+ T cells in liver2 Clinical and Developmental Immunology
tissues, the contribution of CXCR3 to the recruitment of
T cells to these inﬂamed tissues was not well established.
Moreover, it was unclear whether CXCR3 was essential for
migration to this inﬂamed tissue in PBC.
In this study, we hypothesized that CXCR3 played
important role in T cell migration to sites of inﬂammation
in PBC, and CXCR3 gene deﬁciency would terminate or
attenuate the severity of PBC. To address this hypothesis,
we used CXCR3 knockout (CXCR3−/−) mice and their wild-
type (WT) littermates to investigate the contribution of
CXCR3 in PBC.
2.MaterialsandMethods
2.1. Mice. Four groups of C57BL/6 background mice, 10 to
12weeksold(20–22gramsofweight),24ineachgroup,were
used for this experiment: Group I, WT control mice, which
were injected intraperitoneally with sterilized phosphate-
buﬀered saline (PBS); Group II, CXCR3−/− control mice,
which were injected with PBS; Group III, WT PBC mice,
which were injected with Polyinosinic polycytidylic acid
(Poly I:C) and Group IV, CXCR3−/− PBC mice, which
were injected with poly I:C. The mice were sacriﬁced by
cervical dislocation at weeks 8, 16, and 24, respectively, after
administration of poly I:C or PBS. Eight mice were sacriﬁced
in every group at diﬀerent time point. Three mice had died
before test time point. CXCR3−/− mice with C57BL/6 back-
ground had been established by gene targeting as described
elsewhere and were kindly provided by Dr. Bao LU (Harvard
Medical School, Boston, Mass, USA). CXCR3−/− mice and
WT littermate mice (Experimental Animal Research Center,
Beijing, China) with C57BL/6 background (backcross more
than 14 generations) were maintained in a pathogen-free
Mjplouse facility at Peking Union Medical College (Beijing,
China).
2.2.PolyI:CInjection. PolyI:CwasobtainedfromInvivogen.
It was dissolved in sterilized water at a concentration of
1mg/mLandstoredat−20◦C until needed. Female C57BL/6
mice were injected with poly I:C (1mg/kg of body weight)
intraperitoneally twice a week for 24 consecutive weeks. As
controls, a group of female C57BL/6 mice was injected with
PBS.
2.3. Preparation of Splenocytes and Liver-Inﬁltrating Lympho-
cytes. Lymphocyteswereisolatedfromliversorspleensusing
nonenzymatic, mechanical methods to preserve chemokine
receptor expression. After mice were sacriﬁced, the abdomen
was opened, and the portal vein was cut to create an outlet.
The caval vein was then cannulated and perfused with 5 to
10mL of PBS. Perfused livers and spleens were homogenized
in 20mL of Hank’s balanced salt solution (HBSS) by passing
the tissue through a ﬁne nylon mesh, and cells were pelleted
by centrifugation at 500×g. Pellets were resuspended by PBS
and added over Ficoll density gradients. Mononuclear cells
were then pelleted by 20min of centrifugation at 1000×g.
Isolated lymphocytes were resuspended in RPMI 1640.
2.4. Flow Cytometric Analysis. Splenocytes and liver-
inﬁltrating lymphocytes were prepared by centrifugation
over Ficoll density gradients and were incubated with
phycoerythrin- (PE-) conjugated anti-CXCR3, Fluorescein
isothiocyanate- (FITC-) conjugated anti-CD4 or anti-CD8,
or Phycoerythrin-Cy5- (PE-Cy5-) conjugated anti-CD3,
which were purchased from eBioscience company. Flow
cytometric analysis was performed on FACScan ﬂow
cytometer (Coulter EPICS XL).
2.5. Detection of Autoantibodies. Two methods were em-
ployed to detect autoantibodies in the mice serum. The
existence of autoantibodies, including antinuclear antibody
(ANA),antimitochondrialantibody(AMA),andantismooth
muscle antibody (SMA), was ﬁrstly examined by staining
Hep (Human epidermoid cancer cells)-2 cells using indirect
immunoﬂuorescent technique. The Euroimmun anti-M2-
3E ELISA (IgG) test kit provides a semiquantitative in
vitro assay for autoantibodies of the immunoglobulin class
againstthemitochondrialantigensM2inserumaccordingto
the manufacture’s protocol. Horseradish peroxidase- (HRP-)
conjugated aﬃnity puriﬁed goat antimouse IgG (Jackson
ImmunoResearch Laboratories) was used as a secondary
antibody. Photometric measurement was made at a wave-
length of 450nm.
2.6. IP-10/CXCL10 ELISA. ELISA kit speciﬁc to murine IP-
10 was purchased from R&D Systems. This assay employed
the quantitative sandwich enzyme immunoassay technique.
ApolyclonalantibodyspeciﬁcformouseIP-10hadbeenpre-
coated onto a microplate. Standards, controls, and samples
were pipetted into the wells. The concentrations of CXCL10
in the sera were determined by ELISA kits according to the
manufacturer’s recommendations.
2.7. Histopathology and Immunohistochemical Examination.
Formalin-ﬁxed,paraﬃn-embeddedtissueswereusedforhis-
tological evaluation. After deparaﬃnization, various tissues
were stained with hematoxylin and eosin (H&E staining).
The extent of inﬁltrating cells in the liver tissues was
evaluated by light microscopy. Expression of CXCR3, CD4
and CD8 was detected by immunohistochemistry using
rabbitanti-mouseCXCR3,anti-mouseCD4,andanti-mouse
CD8 (Beijing Biosynthesis Biotechnology CO, LTD) diluted
1:1000, respectively.
2.8. Statistical Analysis. Data were expressed as the mean
value ± SEM of the number of samples evaluated. Student’s
t-test or ANOVA was used to evaluate the signiﬁcance of
the diﬀerences. Statistical analysis was performed with SPSS
version 11.5, with a value of P less than .05 regarded as
statistically signiﬁcant.
3. Results
3.1. Clinical Features of Female C57BL/6 Mice Injected with
Poly I:C. Liver function tests were performed in all theClinical and Developmental Immunology 3
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Figure 1: A representative staining pattern of autoantibodies from the sera of female C57BL/6 mice injected with poly I:C and control mice.
No autoantibody was detected in the sera from control mice (a, c, e). The presence of anti-mitochondrial antibody (b), anti-smooth muscle
antibody, (d) and antinuclear antibody (f) was evaluated by immunoﬂuorescence method.4 Clinical and Developmental Immunology
Table 1: The serum autoantibodies detected by indirect immunoﬂuorescence in PBC mice.
Type of Abs
WT PBC mice Positive/total number CXCR3−/− PBC mice Positive/total number
8 weeks 16 weeks 24 weeks 8 weeks 16 weeks 24 weeks
ANA 3/8 5/8 5/7∗ 2/8 4/7∗ 5/7∗
AMA 3/8 6/8 7/7∗ 4/8 5/7∗ 6/7∗
SMA 1/8 2/8 1/7∗ 0/8 1/7∗ 2/7∗
∗Every group was consisted of 8 mice. There were seven mice because 1 mouse had died before test.
8wWTPBCmice
8w CXCR3−/− PBC mice
8w control mice
16w WT PBC mice
16w CXCR3−/− PBC mice
16w control mice
24w WT PBC mice
24w CXCR3−/− PBC mice
24w control mice
0 40 80 120
(IU/L)
Figure 2: AMA titers in the control and PBC mice sera measured
by ELISA.
control and PBC model mice. Serum alanine aminotrans-
ferase (ALT) and alkaline phosphatase (ALP) levels were
raised among WT PBC mice compared with WT control
mice (48.45 ± 24.69IU/L versus 27.00 ± 7.78IU/L, P =
.043; 117.74 ± 38.02IU/L versus 71.17 ± 8.61IU/L, P =
.005), as well as serum total bilirubin (TBIL) levels (1.89 ±
1.12μmol/L versus 0.24 ± 0.12μmol/L, P = .001). Serum
levels of ALT, ALP, and TBIL of CXCR3−/− PBC mice were
46.70 ± 19.18,108.40 ± 28.08IU/L, and 1.68 ± 1.04μmol/L
respectively. Although ALT levels were found to be elevated
in all PBC model mice regardless of genotype compared to
CXCR3−/− PBC mice, WT PBC mice had higher TBIL level
in the serum, but with no statistical signiﬁcance (2.08 ±
1.19μmol/L versus 1.68 ± 1.04μmol/L), as well as ALP level
(117.72 ±38.54IU/L versus 108.40 ±28.08IU/L).
3.2. Development of Autoantibodies in Female C57BL/6 Mice
Injected with Poly I:C. Autoantibodies were detected in all
experimental mice. As shown in Figure 1,av a r i e t yo f
autoantibodies were detected in the sera from poly I:C-
injected mice, including AMA, ANA, and SMA. By 24 weeks,
allofthepolyI:C-injectedmiceexhibitedmorethanonetype
of autoantibodies (Table 1).
Serum AMA was measured by ELISA (Figure 2). AMA
titers were increased in the WT PBC mice compared with
WT control mice (78.69 ± 39.04 versus 18.82 ± 9.06IU/L,
P = .001). There was no signiﬁcant diﬀerence between AMA
titers in the serum of WT PBC mice and CXCR3−/− PBC
mice (78.69 ± 39.04 versus 80.14 ± 39.27IU/L) or between
diﬀerent time points (data not shown).
3.3. Surface Expression of CXCR3 on CD3+,C D 4 +,a n d
CD8+ Cells. Splenocytes and liver-inﬁltrating lymphocytes
of eighteen WT mice including nine control mice and nine
PBC model mice were tested by ﬂow cytometry. To analyze
the expression of CXCR3 on lymphocytes, splenocytes were
stained from WT control mice with anti-CD4, anti-CD8,
anti-CD3, anti-CD19, and anti-CXCR3 mAb. A represen-
tative result of the ﬂow cytometry analysis was shown in
Figure 3. CXCR3 were expressed predominantly on CD3+
cells, rather than CD19+ cells. The percentage of CXCR3+
cells was higher in the CD8+ T cell population than that in
the CD4+ cells (Figure 3).
To determine whether distinct subsets of peripheral
immune cells are selectively recruited to the liver, we
examined the expression of CXCR3 on liver-inﬁltrating lym-
phocytes at week 8, 16 and 24 (Figure 4)b yﬂ o wc y t o m e t r y
which demonstrated a signiﬁcantly higher proportion of
CXCR3 expressed on CD3+,C D 4 + and CD8+ cells in liver
than in spleen, especially in the WT PBC model mice.
Compared to control model, the proportion of cells positive
for CXCR3 was increased in the intrahepatic inﬁltrates of
WT PBC mice, with signiﬁcant diﬀerence on CD8+ Tc e l l s
(P = .039) (Figures 4(a), 4(b),a n d4(c)). Furthermore,
the proportion of CD3+ and CD8+ splenocytes positive for
CXCR3 was signiﬁcantly higher in WT control mice than in
WT PBC mice (P = .002 and P = .019) (Figure 4(c)).
High percentage of CXCR3+ cells in the liver suggested
thatCXCR3+ lymphocyteswererecruitedtotheliverthrough
speciﬁc mechanisms. The high expression of CXCR3 might
be an important event in migration of T cells to sites of
inﬂammation.
3.4. Analysis of IP-10/CXCL10 in the Mice Sera. The serum
level of IP-10/CXCL10 in all PBC and control mice was ana-
lyzed. Signiﬁcantly increased serum levels of IP-10/CXCL10
were observed in WT PBC models as compared with control
subjects (0.38 ± 0.25 versus 0.09 ± 0.04, P = .002). With the
disease progression, IP-10/CXCL10 level was elevated grad-
ually. Furthermore, during 8-weeks and 16-weeks periods,
IP-10/CXCL10 increased slightly in CXCR3−/− PBC mice
without statistical signiﬁcance compared with WT PBC mice
(0.39±0.18versus0.28±0.10atweek8and0.46±0.45versus
0.33 ± 0.19 at week 16). In 24-weeks period, IP-10/CXCL10
serum level increased signiﬁcantly in CXCR3−/− PBC mice
compared with WT PBC mice model (0.51 ± 0.23 versus
0.27 ±0.11, P = .046).Clinical and Developmental Immunology 5
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Figure 3: A representative data showed surface expression of CXCR3 on CD3+,C D 1 9 +,C D 4 +, and CD8+ cells on splenocytes from WT
control mice.
3.5. Histological Features of the PBC Model Liver. After
injection with 5mg/kg of poly I:C, diﬀerent degrees of
lymphocytic inﬁltration surrounding the small bile ducts
were detected within the portal tracts (HE staining) in
WT C57BL/6 mice. Representative staining patterns of
mononuclear cell inﬁltration in the liver tissues are shown
in Figure 5. Mononuclear cell inﬁltration in the liver tissues
was detected at 8 weeks after poly I:C injection Figures
5(a),a n d5(b) and progressively increased with time. A
representative staining pattern of portal areas at 16 weeks
after the start of poly I:C injection is shown in Figures
5(e), 5(f), which reveals irregular nuclear arrangement of
interlobular bile ducts, distorted lumen and detachment
of cells, as well as inﬁltrating cells accumulated around
the damaged bile duct, resembling chronic nonsuppurative
destructive cholangitis as seen in PBC. In 24-week period,
theinterlobularbileductswerelost,bileplugswereevidentin
the livers of WT PBC mice, and granulomas formation was
detected as well (Figures 5(i),a n d5(k)). Furthermore there
was a mild interface hepatitis (piecemeal necrosis), and, in a
few instances, inﬁltrates were evident adjacent to the central
vein.
By comparing histological changes of CXCR3−/− PBC
mice with WT PBC mice, we analyzed hepatic inﬂammation
and granuloma’s formation in the livers of PBC models of
WT and CXCR3−/− mice. The results showed there was
signiﬁcantreductionofinﬂammationfociandinﬂammatory
cells in the livers of CXCR3−/− PBC mice than that in WT
PBC mice at weeks 8, 16. Furthermore, at week 24, there
was no cholestasis or granulomas in CXCR3−/− PBC mice.
These ﬁndings indicated that CXCR3−/− mice had a delayed
onset and insuﬃcient recruitment of inﬂammatory cells to
the liver.
3.6. Immunohistochemical Examination Results. As shown in
Figure 6, immunohistochemical analysis of liver consistently
conﬁrmed that, in PBC model mice, there were numerous
of CD4+ and CD8+ lymphocytes inﬁltrated in portal area
which was absent in control mice. The distribution of CD4+
CXCR3+ and CD8+ CXCR3+ cells was similar. Moreover,
CXCR3+ mononuclear cells were found mainly in the
enlarged portal tracts, localized near the bile ducts, especially
along the periportal areas (Figure 6(f)). Few CD4+ or CD8+
T cells were seen in hepatic lobules.6 Clinical and Developmental Immunology
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Figure 4: Expression of CXCR3 on T cells in control and PBC mice. (a) Expression of CXCR3 on CD3+,C D 4 +, and CD8+ intrahepatic
lymphocytes in the control mice. (b) Expression of CXCR3 on CD3+,C D 4 +, and CD8+ intrahepatic lymphocytes in WT PBC mice. (c)
Comparison between expression of CXCR3 on CD3+CD4+, and CD3+CD8+ lymphocytes in WT control and PBC mice. Data are depicted
as the mean value ± SEM of percentages. Statistical signiﬁcance is determined by the one-tailed paired two-sample Student’s t-test and is
indicated as follows: ∗P<. 05.Clinical and Developmental Immunology 7
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Figure 5: Serial observation of mononuclear cells inﬁltration in the liver tissue. Female C57BL/6 mice were injected with 5mg/kg of poly
I:C twice a week for 24 consecutive weeks. Liver specimens were collected at 8 weeks (a–d), 16 weeks (e–h), and 24 weeks (i–l) after the start
of poly I:C injection and were underwent HE staining. Diﬀerent degrees of lymphocytic inﬁltration surrounding the small bile ducts were
detected within the portal tracts. A representative staining pattern from each period is shown as following: (a, b) Week 8 of WT PBC mice.
(c, d) Week 8 of CXCR3−/− PBC mice. (e, f) Week 16 of WT PBC mice. (g, h) Week 16 of CXCR3−/− PBC mice. (I, k) Week 24 of WT PBC
mice. (j, l) Week 24 of CXCR3−/− PBC mice. Note: Magniﬁcation: (a, c, e, g, i, j) × 5 ;( b ,d ,f ,h ,k ,l )× 20, × 40.
4. Discussion
CXCR3isaGprotein-coupled,seven-transmembranerecep-
tor found predominantly on T cells that binds and is
activated by the three IFN-gamma-inducible chemokines of
theCXCfamilynamedCXCL9,CXCL10,andCXCL11[4,5].
Their major function is to selectively recruit immune cells at
inﬂammation sites, but they also play a role in angiogenesis
mechanisms [33]. In the last few years, strong experimental
and clinical evidence has been obtained supporting the idea
that the CXCR3 pathway is involved in the development of
autoimmune diseases, thereby inducing worsening ofclinical
manifestations [8–17]. CXCL10 is a 10kD protein, which is
categorized functionally as a Th1-chemokine. It binds to the
receptor CXCR3 and regulates immune responses through
the activation and recruitment of leukocytes [6]. Recent
reports have shown that serum and/or tissue expressions of
CXCR3 and CXCL10 are increased in various autoimmune
diseases, which may have important roles in leukocyte
homing to inﬂamed tissues and in the perpetuation of
inﬂammation, and therefore, tissue damage [5, 6]. Although
previous studies in human PBC have shown the presence of8 Clinical and Developmental Immunology
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Figure 6: Immunohistochemical staining of liver from PBC model mice. Representative results of immunohistochemical staining of CD4,
CD8, and CXCR3 in the early and late stage of PBC were shown as follows (×20 magniﬁcations): (a) CD4+ lymphocytes at week 8; (b) CD8+
lymphocytesatweek8;(c)CXCR3+ lymphocytesatweek8;(d)CD4+ lymphocytesatweek24;(e)CD8+ lymphocytesatweek24;(f)CXCR3+
lymphocytes at week 24.
CXCR3+ T cells in liver tissues, the contribution of CXCR3
to the recruitment of T cells to these inﬂamed tissues is not
well established [31]. Also, it is unclear whether CXCR3 is
essential for migration to this inﬂamed tissue.
Inthisstudy,WTC57BL/6miceandCXCR3−/− C57BL/6
micewereusedtoestablishPBCmicemodel,whichhadbeen
demonstrated by Okada et al. [34]. We investigated whether
CXCR3wasinvolvedinthepathogenesisofPBC,bymethods
of IIF, ELISA, pathology, immunohistochemistry, and ﬂow
cytometry.
First, we analyzed the pathologic character of WT mice
injected with poly I:C. In our study, moderate to severe
lymphocytes inﬁltration was detected within the portal
tracts in association with bile duct damage, occurring only
in the mice injected with poly I:C, resembling those of
chronic nonsuppurative destructive cholangitis as seen in
PBC. Moreover, it was diﬃcult to identify an intact bile
ductstructurebecausebiliarycelldestructionwassuﬃciently
advanced in liver tissues from the poly I:C-injected mice.
A si ll u s tra t edi ns ecti o n so fl i v e r ,po rt a ltract so fl i v e r so fP B C
model mice contained moderate inﬁltrates of mononuclear
cells associated with biliary ductular damage. Interlobular
bile ducts showed an irregular nuclear arrangement, a
distorted lumen and detachment of cells from the basement
membrane, similar to that seen in advanced human PBC.
Secondly, we analyzed the serum AMA level in control
mice, WT mice, and CXCR3−/− mice which were injected
with poly I:C. In human PBC, the severity and temporal
progression vary widely among patients and do not correlate
with AMA titers. In this study, a variety of autoantibodies
were detected positive in the sera from poly I:C-injected
mice, including AMA, ANA, and SMA. The results suggested
that the poly I:C-injected mice not only had the inﬂamma-
tory inﬁltration around portal tracts, but also showed some
character of autoimmune hepatitis. In addition, there was no
signiﬁcantdiﬀerencebetweenAMAtitersintheserumofWT
mice and CXCR3−/− mice, or between diﬀerent period of
PBC, which revealed that the disease severity varied widelyClinical and Developmental Immunology 9
among diﬀerent period mice injected with poly I:C, but
did not correlate with AMA titers, both in WT mice and
CXCR3−/− mice.
Next, the functional importance of CXCR3 in the liver of
PBC mice model was investigated by ﬂow cytometry, which
conﬁrmed the selective recruitment of CXCR3+ lymphocytes
into the liver. We found the increased expression of CXCR3
in the liver after poly I:C injection as well as its ligands
IP-10/CXCL10 in the serum. We analyzed paired samples
of liver inﬁltrating lymphocytes and splenocytes from PBC
model mice and control mice and detected the expression of
CXCR3 in the liver there was greater expression of CXCR3
than that from spleen. Compared to control model, the
proportion of cells positive for CXCR3 was increased in the
intrahepatic inﬁltrates in PBC model, chieﬂy on CD8+ T
cells; furthermore, the proportion of CXCR3+ cells expressed
on CD3+ and CD8+ cells was markedly decreased in the
splenocytes in PBC model. The preferential accumulation of
CXCR3+ cells in liver and increased level of its ligand IP-
10/CXCL10 in serum suggested that CXCR3 expressing cells
migrated to the liver in a much larger number than T cells
lacking this chemokine receptor. Therefore, CXCR3 might
play a great role in recruiting T cells, especially CD8+ T
cells to liver tissues in PBC disease model. In addition, using
immunohistochemistry we demonstrated that all the PBC
models showed CXCR3-expressing lymphocytes inﬁltrating
the liver.
Forth, importantly, we directly demonstrated an impor-
tant role for CXCR3 in inﬂammatory cells recruitment to
inﬂamed liver in PBC by comparing the pathologic result
of WT mice, and CXCR3−/− mice. Although the statistically
signiﬁcant decrease of liver function test, including ALP and
TBIL, was not achieved in CXCR3−/− PBC mice compared
with WT PBC mice, the histopathological results conﬁrmed
the eﬀect of CXCR3 to the recruitment of inﬂammatory cells
in PBC model disease development. In the WT mice injected
with poly I:C, moderate to severe lymphoid cell inﬁltration
was detected within the portal tracts in association with bile
duct damage. Compared to WT mice, although the same
t i t e ro fA M Aw a sp r o d u c e di nC X C R 3 −/− mice injected with
poly I:C, there was marked reduction in total inﬂammatory
cells in the liver over 8- and 16- week periods, leading
to insuﬃcient inﬂammatory cells inﬁltration. Moreover,
cholestasis and ﬁbrosis were not detected in PBC model
of CXCR3−/− mice in 24 weeks. These ﬁndings provided
direct evidence that CXCR3 could mediate inﬂammatory
cells recruitment to inﬂamed tissues in liver and, hence,
had a major role in inﬂammation of PBC model mice.
Nevertheless, knockout CXCR3 could reduce the severity
of the disease but not entirely eliminate inﬂammatory cells
inﬁltration in the liver. This observation strongly suggested
that CXCR3 on T cells might play an important but not
absolutely essential role in T cells recruitment to inﬂamed
liver tissues and other CXCR3-independent pathways also
mediated recruitment in the disease development.
The limit of this study is that there were a variety of
autoantibodies tested in the PBC mice model, including
AMA, ANA, and SMA, indicating some character of autoim-
mune hepatitis and other sites of inﬂammation. Salivatitis,
pancreatitis, and interstitial nephritis were demonstrated in
the article of Okada et al. [34]. Further studies with more
speciﬁc PBC models are needed.
In conclusion, this study directly demonstrated that
chemokineIP-10anditsreceptorCXCR3promotetheaction
of lymphocytes in PBC model and that CXCR3 knockout
dramatically reduces the severity and inﬂammatory reaction
in PBC. Given the role that CXCR3 and its ligands play
in induction of hepatic damage, prevention of CXCR3
engagement may be beneﬁcial for the treatment during the
lymphocytes inﬁltration period.
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